Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1180 SEMINOLE TRAIL, SUITE 495 CHARLOTTESVILLE VA 22901 |
Tel: | 1-212-6711021 |
Website: | https://www.adialpharma.com |
IR: | See website |
Key People | ||
Cary J. Claiborne President, Chief Executive Officer, Director | Joseph Truluck Chief Financial Officer, Treasurer, Secretary | Tony Goodman Chief Operating Officer, Director | Bankole A. Johnson Chief Medical Officer |
Business Overview |
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. The Company's drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder (AUD). AD04 is used for the treatment of AUD in subjects with certain target genotypes, which were identified using its companion diagnostic genetic test. AD04 is a genetically targeted, serotonin-3 receptor antagonist, a therapeutic agent for the treatment of AUD. The Company's AD04 also has the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders. |
Financial Overview |
For the fiscal year ended 31 December 2023, Adial Pharmaceuticals Inc revenues was not reported. Net loss before extraordinary items decreased 35% to $7M. Lower net loss reflects General and Administrative Expenses decrease of 29% to $4.1M (expense), Equity-based compensation decrease of 51% to $1.5M (expense), Research and development expenses - decrease of 38% to $1.1M (expense). |
Employees: | 4 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $4.07M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$6.89M as of Dec 31, 2023 |
Net annual income (TTM): | -$7.00M as of Dec 31, 2023 |
Free cash flow (TTM): | -$6.81M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 4,054,861 as of Mar 29, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |